Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypocellular bone marrow with increased blasts.

C L Gladson, F Naeim

    American Journal of Hematology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Hypocellular bone marrow with increased blasts (HBMIB) is a distinct entity. Patients with HBMIB face severe marrow failure and poor chemotherapy response, indicating a poor prognosis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Xenoantisera to human DR antigens: Serological and immunochemical characterization.

    Immunogenetics·2011
    Same author

    HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.

    Oncogene·2005
    Same author

    TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate.

    Oncogene·2001
    Same author

    1998 Neurotumor Club. March 30, 1998, New Orleans, La.

    Neuro-oncology·2001
    Same author

    Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions.

    Oncogene·2000
    Same author

    p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo.

    Journal of cell science·2000
    Same journal

    High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

    American journal of hematology·2026
    Same journal

    Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

    American journal of hematology·2026
    Same journal

    Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

    American journal of hematology·2026
    Same journal

    Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

    American journal of hematology·2026
    Same journal

    Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

    American journal of hematology·2026
    Same journal

    Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

    American journal of hematology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Pathology

    Background:

    • Hypocellular bone marrow with increased blasts (HBMIB) presents a diagnostic challenge.
    • Understanding the clinicopathologic features of HBMIB is crucial for patient management.

    Purpose of the Study:

    • To characterize the clinicopathologic features of hypocellular bone marrow with increased blasts (HBMIB).
    • To evaluate the treatment response and outcomes in patients with HBMIB.

    Main Methods:

    • Retrospective review of 20 patients diagnosed with HBMIB.
    • Analysis of bone marrow morphology, blast cell characteristics, and special stain results.
    • Evaluation of patient history, treatment modalities, and survival data.

    Main Results:

    Related Experiment Videos

    • HBMIB patients had a median age of 60, with a male predominance.
    • Characteristic features included pancytopenia, hypocellular marrow (≤35%), and increased blast cells with myeloid morphology.
    • Chemotherapy was associated with high mortality; only 2 patients progressed to overt leukemia.

    Conclusions:

    • HBMIB represents a distinct clinicopathologic entity characterized by severe marrow failure.
    • Patients with HBMIB exhibit a low response rate to chemotherapy and a generally poor prognosis.
    • Further research into novel therapeutic strategies for HBMIB is warranted.